Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2008

View Archived Issues

Inspire initiates second phase III denufosol tetrasodium trial in cystic fibrosis

Cellegy enters definitive merger agreement with Adamis

Dara BioSciences and Point Therapeutics consummate merger

Altor signs agreement with Genentech for antibody-based tissue factor antagonists

Serotonin system involved in chronic L-DOPA wearing-off effect

Recent Amgen patent discloses new treatment for idiopathic pulmonary fibrosis

Results from Merck & Co. HIV vaccine reported at the CROI meeting

Sublingual route effective for influenza vaccine in mice

Robust immune responses with multiclade HIV-1 DNA plasmid vaccine in phase I/II studies

EMEA accepts for filing sanofi pasteur's MAA for seasonal influenza vaccine

Mesoblast reports positive results from clinical trial of adult stem cells in fracture healing

FDA issues special protocol assessment to Wilex for phase III trial of CA9-SCAN

Raven completes enrollment in phase I/IIa clinical trial of RAV-12 therapeutic antibody

Lipoxen and the Serum Institute of India initiate dosing in phase I trial of ErepoXen

Novel anti-HIV agents described in recent Merck patent

New therapeutic agents for HCV infection reported in recent patent literature

Bioniche presents update on Urocidin trial in refractory bladder cancer

FDA grants fast track status to Boehringer Ingelheim's BIBW-2992 for NSCLC

Qiagen and Center for Molecular Medicine research molecular diagnostic markers

YM Biosciences enrolls first patient in phase II nimotuzumab trial in brain cancer

Dainippon Sumitomo recaps Q3 developments

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.